GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » Other Current Receivables

BioPharma Credit (LSE:BPCR) Other Current Receivables : $0.0 Mil (As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit Other Current Receivables?

BioPharma Credit's Other Current Receivables for the quarter that ended in Dec. 2022 was $0.0 Mil.


BioPharma Credit Other Current Receivables Historical Data

The historical data trend for BioPharma Credit's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPharma Credit Other Current Receivables Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Receivables
Get a 7-Day Free Trial - - - - -

BioPharma Credit Semi-Annual Data
Jun17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Dec23
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioPharma Credit Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable and Other Current Receivables under the "Total Receivables" section.


BioPharma Credit Other Current Receivables Related Terms

Thank you for viewing the detailed overview of BioPharma Credit's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPharma Credit (LSE:BPCR) Business Description

Traded in Other Exchanges
N/A
Address
65 Gresham Street, 6th Floor, London, GBR, EC2V 7NQ
BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit (LSE:BPCR) Headlines

No Headlines